AARD Stock Summary and Trading Ideas (Aardvark Therapeutics | NASDAQ:AARD)

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Aardvark Therapeutics trades on the NASDAQ stock market under the symbol AARD.

As of September 3, 2026, AARD stock price declined to $5.73 with 88,418 million shares trading.

AARD has a beta of 3.95, meaning it tends to be more sensitive to market movements. AARD has a correlation of 0.15 to the broad based SPY ETF.

AARD has a market cap of $125.40 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that AARD belongs to (by Net Assets): VTI, VXF, IBB, IWC, BUSM.

AARD has underperformed the market in the last year with a price return of -35.3% while the SPY ETF gained +21.9%. However, in the short term, AARD had mixed performance relative to the market. It has outperformed in the last 3 months, returning +44.3% vs +2.0% return in SPY. But in the last 2 weeks, AARD shares have been beat by the market, returning -15.1% compared to an SPY return of +0.5%.

AARD support price is $5.47 and resistance is $6.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AARD shares will trade within this expected range on the day.